Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis

NCT02983227 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02983227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02983227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
July 17, 2019
Enrollment
496 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis